Squamous cell carcinoma - Okasolusyöpä
☆ Saksan vuoden 2022 Stiftung Warentest -tuloksissa kuluttajien tyytyväisyys ModelDermiin oli vain hieman alhaisempi kuin maksullisiin telelääketieteen konsultaatioihin.
Squamous cell carcinoma well differentiated ― Havaitaan viereinen aktiininen keratoosi.
References
Squamous cell carcinoma (SCC) on toiseksi yleisin ihosyöpä Yhdysvalloissa basal cell carcinoma jälkeen. Se alkaa yleensä esisyövän vaurioista, joita kutsutaan actinic keratosis , ja voi levitä muihin kehon osiin. Pääsyynä on altistuminen auringon ultraviolettisäteilylle (UV-säteilylle) , joka kertyy ajan myötä. Hoito sisältää yleensä kirurgisen poiston, erityisesti pään ja kaulan SCC:n osalta. Sädehoito on vaihtoehto vanhemmille potilaille tai niille, jotka eivät voi tehdä leikkausta. Immunosuppressio lisää SCC:n riskiä. Vaikka SCC on harvinaista, se voi levitä, etenkin potilailla, joiden immuunijärjestelmä on heikentynyt. Säännölliset tarkastukset ja aurinkosuoja ovat tärkeitä SCC:tä sairastaville.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) on ihmisten toiseksi yleisin syöpä, ja sen määrä on nousussa. Vaikka CSCC:llä on yleensä hyvänlaatuinen kliininen käyttäytyminen, se voi levitä sekä paikallisesti että muihin kehon osiin. Tutkijat ovat tunnistaneet tiettyjä CSCC-kehitykseen liittyviä polkuja, jotka johtavat uusiin hoitoihin. Mutaatioiden suuri määrä ja lisääntynyt riski immunosuppressoituneilla potilailla ovat saaneet aikaan immunoterapian kehittämisen. Tässä katsauksessa tarkastellaan CSCC:n geneettisiä juuria ja uusimpia tiettyihin molekyyleihin ja immuunijärjestelmään kohdistuvia hoitoja.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnostiikka ja hoito
#Dermoscopy
#Skin biopsy